ArticleEuropean journal of clinical investigation2026
Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors.
Article in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICI) are widely used in cancer therapy, but biomarkers for thromboembolic risk, treatment response, and survival remain limited. We evaluated the association of systemic inflammatory indices with these clinical outcomes.
methodsIn this retrospective cohort study, 580 ICI-treated patients at the Medical University of Vienna, Austria, were included. Inflammatory indices including neutrophil-lymphocyte-ratio (NLR), platelet-lymphocyte-ratio (PLR), lymphocyte-monocyte-ratio (LMR), systemic immune-inflammation-index (SII) and C-reactive-protein-albumin-ratio (CAR) were calculated at ICI-start and longitudinally within 3 months. Co-primary outcomes were risk of venous thromboembolism (VTE), assessed using competing risk analysis, and overall- and progression-free-survival (OS/PFS), evaluated with Cox regression, whereas longitudinal biomarker dynamics were analysed using time-dependent analyses.
resultsHigher baseline NLR (HR 1.65, 95% CI: 1.28-2.12), CAR (HR 1.99, 95% CI: 1.67-2.38), and SII (HR 1.18, 95% CI: 1.00-1.39) were independently associated with shorter OS, while higher LMR (HR 0.44, 95% CI: 0.30-0.67) was associated with longer survival. For PFS, elevated NLR (HR 1.29, 95% CI: 1.05-1.57), higher PLR (HR 1.18, 95% CI: 1.00-1.39), lower LMR (HR 0.57, 95% CI: 0.43-0.70), and higher CAR (HR 1.42, 95% CI: 1.28-1.62) predicted poorer outcomes. None of the indices at treatment start were associated with VTE, yet doubling of levels within 3 months indicated higher VTE risk for PLR (sub-distribution hazard ratio [SHR]: 3.03 95% confidence interval [CI]: 1.05-8.08) and a borderline-significant association for CAR (SHR: 2.02, 95% CI: 0.89-4.60).
conclusionWe found that selected inflammatory indices were associated with poor OS and PFS in ICI-treated patients, and longitudinal dynamics might identify patients at higher risk for VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.